A Phase II Randomized Study of Palbociclib in Combination With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer

Trial Profile

A Phase II Randomized Study of Palbociclib in Combination With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Palbociclib (Primary) ; Capecitabine; Exemestane; Goserelin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 03 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top